Provided by Tiger Fintech (Singapore) Pte. Ltd.

TNF Pharmaceuticals, Inc.

0.3680
+0.02106.05%
Post-market: 0.36990.0019+0.52%19:46 EDT
Volume:139.63K
Turnover:48.79K
Market Cap:1.01M
PE:-0.03
High:0.3680
Open:0.3443
Low:0.3443
Close:0.3470
Loading ...

Company Profile

Company Name:
TNF Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
6
Office Location:
855 N. Wolfe Street,Suite 623,Baltimore,Maryland,United States
Zip Code:
21205
Fax:
- -
Introduction:
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Directors

Name
Position
Joshua Silverman
Chairman of the Board
Mitchell Glass
Principal Executive Officer and Director,President and Chief Medical Officer
Bill J. White
Director
Christopher C. Schreiber
Director
Craig Eagle
Director
Jude Uzonwanne
Director
Stephen Friscia
Director

Shareholders

Name
Position
Ian Rhodes
Interim Chief Financial Officer
Mitchell Glass
Principal Executive Officer and Director,President and Chief Medical Officer